Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure

Eur J Heart Fail. 2019 May;21(5):624-633. doi: 10.1002/ejhf.1428. Epub 2019 Feb 17.

Abstract

Aims: The clinical significance of the measurement of urine sodium concentration (UNa+ ) in response to loop diuretic administration in patients with acute heart failure (AHF) is still unsettled. We studied the association of serial measurements of spot UNa+ during the first 48 h of AHF treatment with the indices of decongestion, renal function, and prognosis.

Methods and results: We enrolled 111 AHF patients, all of whom received intravenous furosemide on admission. The mean spot UNa+ significantly increased in the 6 h sample (P < 0.05 vs. baseline) and returned to baseline values in the 24 and 48 h samples. Based on the increase or decrease/no change of UNa+ in the 6 and 48 h samples vs. baseline, patients were divided into two groups at each time point, respectively. Patients did not differ in baseline clinical and laboratory characteristics. Patients with a decrease/no change of UNa+ in the 6 and 48 h samples had a lower weight loss during hospitalization. Patients with a decrease/no change of UNa+ in the 48 h sample had a poorer diuretic response and a significant increase in the urinary levels of the tubular biomarkers: kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin. Low UNa+ and decrease/no change in UNa+ in the 6 and 48 h samples were independent predictors of higher risk of all-cause mortality during 1-year follow-up (all P < 0.05).

Conclusion: In AHF, low spot UNa+ and lack to increase UNa+ in response to intravenous diuretics are associated with poor diuretic response, markers of tubular injury and high risk of 1-year mortality.

Keywords: Acute heart failure; Decongestion; Kidney injury; Mortality; Urine sodium.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Administration, Intravenous
  • Aged
  • Edema, Cardiac / physiopathology
  • Female
  • Furosemide / therapeutic use*
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Heart Failure / urine
  • Hepatitis A Virus Cellular Receptor 1 / metabolism
  • Hospitalization
  • Humans
  • Lipocalin-2 / urine
  • Male
  • Middle Aged
  • Prognosis
  • Prospidium
  • Sodium / urine*
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use*
  • Treatment Outcome

Substances

  • HAVCR1 protein, human
  • Hepatitis A Virus Cellular Receptor 1
  • LCN2 protein, human
  • Lipocalin-2
  • Sodium Potassium Chloride Symporter Inhibitors
  • Furosemide
  • Prospidium
  • Sodium